Breadcrumbs

Antimicrobial utilisation surveillance statistics

Surveillance of antimicrobial usage is a fundamental component of antimicrobial stewardship, and is a required action of hospitals for accreditation according to the National Safety and Quality in Health Service Standard 3 (Preventing and Controlling Healthcare Associated Infections).

National Antimicrobial Utilisation Surveillance Program (NAUSP)

The National Antimicrobial Utilisation Surveillance Program (NAUSP) collects data from over 150 major Australian Hospitals and provides reports of key antibiotic usage rates on a six monthly basis. 

De-identified peer group reports are submitted every six months to the Australian Commission on Safety and Quality in Health Care (ACSQHC). These show aggregated data collected from all NAUSP hospitals, principal referral hospitals and public acute group A hospitals. . Private hospitals are included within their appropriate peer group. Other reports show aggregated data at a state level and de-identified benchmarked data. De-identified reports by peer groups are also available.

Contributor hospitals can access individual usage rate reports which contain charts showing comparators made up of the average of usage at similarly peered hospitals through the NAUSP Portal  since January 2017. Some contributors can access reports for Intensive Care Unit, haematology/oncology, High Dependency Unit and respiratory ward specialities. 

National speciality reports are presented below, along with de-identified benchmarking reports for Intensive Care usage in Principal Referral and acute group A hospitals.

 A detailed NAUSP annual report is produced showing usage of an expanded number of antimicrobials both nationally and in individual Australian public and private hospitals in a de-identified manner.

Reports

Annual reports

2016 NAUSP Annual Report (PDF 6.3MB)

2017 Antimicrobial use in South Australian hospitals

National reports by peer group - July 2017 to June 2019

All contributing hospitals (PDF 947KB)

Principal referral hospitals (PDF 952KB)

Public acute group A hospitals (PDF 961KB)

Public acute group B hospitals (PDF 260KB)

Public acute group C hospitals (PDF 241KB)

National speciality reports - July 2017 to June 2019

Haematology / Oncology (PDF 588KB)

High Dependency Unit (PDF 542KB)

Intensive Care Unit (PDF 566KB)

Respiratory (PDF 504KB)

Statewide reports - July 2017 to June 2019

New South Wales and Australian Capital Territory (PDF 634KB)

Queensland and Northern Territory (PDF 638KB)

South Australia (PDF 644KB)

Tasmania (PDF 539KB)

Victoria (PDF 622KB)

Western Australia (PDF 649KB)

Benchmarking reports - January 2019 to June 2019

New South Wales and Australian Capital Territory with hospital data de-identified (PDF 91KB)

Queensland and Northern Territory with hospital data de-identified (PDF 88KB)

South Australia with hospital data de-identified (PDF 85KB)

Tasmania with hospital data de-identified (PDF 77KB)

Victoria with hospital data de-identified (PDF 89KB)

Western Australia with hospital data de-identified (PDF 87KB)

Principal referral hospitals, de-identified - total hospital use (PDF 390KB)

Principal referral hospitals, de-identified - Intensive Care Unit usage (PDF 314KB)

Public acute group A hospitals, de-identified - total hospital usage (PDF 89KB)

Public acute group A hospitals, de-identified - Intensive Care Unit usage (PDF 88KB)

Public acute group B hospitals, de-identified - total hospital usage (PDF 87KB)

Public acute group C hospitals, de-identified - total hospital usage (PDF 84KB)

Disclaimer

Previously published national total-hospital antibiotic usage trend data may not be accurate because of inconsistent application of surveillance definitions for 29 Queensland public hospitals between 2013 and 2017. A process is underway to obtain and re-analyse Queensland antibiotic usage data, and to publish updated Queensland and national antibiotic usage trend data following the revised analyses.

Acknowledgement

The Australian Commission on Safety and Quality in Health Care provides funding for the development and coordination of NAUSP and analyses of NAUSP data and related reports for the AURA Surveillance System.

Further information

For further information on the antimicrobial utilisation surveillance program, contact the NAUSP coordinator.

^ Back to top